Humana (NYSE:HUM) PT Lowered to $280.00 at Oppenheimer

Humana (NYSE:HUM) had its price objective dropped by research analysts at Oppenheimer from $400.00 to $280.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the insurance provider’s stock. Oppenheimer’s price target suggests a potential upside of 16.65% from the company’s previous close.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. boosted their target price on shares of Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 21st. Bank of America lowered shares of Humana from a “neutral” rating to an “underperform” rating and lowered their target price for the stock from $376.00 to $247.00 in a research report on Wednesday. Morgan Stanley assumed coverage on shares of Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 target price for the company. Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price target on shares of Humana in a research note on Tuesday. Finally, TD Cowen upped their price target on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. One research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $357.24.

Humana Stock Performance

NYSE:HUM opened at $240.03 on Thursday. The firm has a market cap of $28.92 billion, a price-to-earnings ratio of 14.95, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. Humana has a 1-year low of $213.31 and a 1-year high of $530.54. The firm’s fifty day moving average price is $337.70 and its 200 day moving average price is $342.42.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm’s revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the firm earned $8.94 earnings per share. On average, sell-side analysts expect that Humana will post 16.01 EPS for the current year.

Hedge Funds Weigh In On Humana

Large investors have recently modified their holdings of the company. Mendota Financial Group LLC grew its holdings in Humana by 9.2% during the 2nd quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after purchasing an additional 27 shares in the last quarter. Aurora Investment Counsel grew its stake in shares of Humana by 1.3% during the fourth quarter. Aurora Investment Counsel now owns 2,273 shares of the insurance provider’s stock valued at $1,155,000 after acquiring an additional 29 shares in the last quarter. Capital Advisors Ltd. LLC increased its position in shares of Humana by 17.0% during the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after acquiring an additional 31 shares during the last quarter. EP Wealth Advisors LLC lifted its stake in shares of Humana by 1.6% in the fourth quarter. EP Wealth Advisors LLC now owns 2,294 shares of the insurance provider’s stock worth $1,050,000 after acquiring an additional 37 shares in the last quarter. Finally, CarsonAllaria Wealth Management Ltd. boosted its holdings in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after purchasing an additional 39 shares during the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.